UPDATE 1-Drugmaker Merck's quarterly profit beats as Keytruda sales surge [Reuters]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Reuters
Drugmaker Merck's quarterly profit beats as Keytruda sales surge | Reuters Reuters Staff 1 Min Read (Reuters) - Drugmaker Merck & Co ( MRK.N ) topped Wall Street estimates for quarterly profit on Friday as sales of blockbuster cancer drug nearly doubled and the company raised its full-year profit outlook. Sales of Keytruda rose 89.2 percent to $1.67 billion, edging past sales of its rival immunotherapy Opdivo made by Bristol-Myers Squibb ( BMY.N ). Merck’s total sales rose 5.4 percent to $10.47 billion. The company now expects full-year adjusted profit forecast to be between $4.22 and $4.30 per share, up from prior guidance of between $4.16 and $4.28 per share. Net income attributable to the company fell to $1.71 billion, or 63 cents per share, in the second quarter, from $1.95 billion, or 71 cents per share, a year earlier. Excluding items, the company earned $1.06 per share, ahead of the average analyst estimate of $1.03 per share, according to Thomson Reuters I/B/E/S. Reporting
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.MarketBeat
- Wealth Of Korea's 50 Richest On Forbes List Rises To $115 Billion [Forbes]Forbes
- Merck (MRK) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Korea's 50 Richest 2024: AI Frenzy Boosts Combined Wealth To $115 Billion [Forbes]Forbes
- Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To [Seeking Alpha]Seeking Alpha
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 4/11/24 - Form ARS
- 4/11/24 - Form DEFA14A
- 4/11/24 - Form DEF
- MRK's page on the SEC website